Kalypsys, a private, San Diego based, clinical stage pharmaceutical company, seamlessly integrates capabilities in drug discovery, medicinal chemistry and translational medicine with proprietary automated technologies to discover and develop high quality, small molecule drugs - faster and more efficiently than ever before.
Kalypsys has a broad, sustainable pipeline in three therapeutic areas: cardiovascular and metabolic diseases, pain/inflammatory disease and oncology. We currently have three clinical candidates, filed our first IND in 2Q06 (KD3010), and anticipate subsequent IND filings 4Q06 (KD7040) and 3Q07 (KD5170).
Kalypsys' major partnering interest is in establishing a limited number of R&D; alliances in which the parties work collaboratively to advance therapeutic area programs from target screening to clinical candidates and beyond. In addition, Kalypsys is pursuing specific product licensing arrangements.
Kalypsys has raised $172 million to date from recognized and respected healthcare investors. Our strong financial position enables us to invest in the accelerated development of our product pipeline. Current investors include 5AM Ventures, Aravis Ventures, CMEA Ventures, Innovis, Invemed Associates, KT Venture Group, Novartis BioVenture Fund, Sprout Group and Tavistock Life Sciences.